Lilly enters drug-development deal with Immunogen

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Cancer treatment developer Immunogen Inc. said Tuesday it will receive $20 million from Eli Lilly and Co. and could earn about $200 million in milestone payments under a collaboration agreement with the Indianapolis drugmaker.

Immunogen, based in Waltham, Mass., said Lilly will receive some exclusive licenses to use its Targeted Antibody Payload, or TAP, technology to develop cancer treatments.

TAP technology includes a tumor-targeting manufactured antibody with a cancer-killing agent attached. The antibody delivers the agent specifically to tumor cells, where it is released to kill the cells.

Lilly is responsible for developing and selling any products from the agreement, and Immunogen could receive royalties on future sales.

Immunogen also has received milestone payments from Amgen Inc. and French drugmaker Sanofi under development agreements.

Lilly, which makes the antipsychotic Zyprexa and the antidepressant Cymbalta, also includes the cancer drugs Alimta and Gemzar in its product portfolio. Sales for Gemzar have tumbled in recent quarters after the drug lost patent protection. The company also has several potential cancer treatments under development in its product pipeline.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In